This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Twitter Mailbag: Gilead, Chelsea, Keryx, Onyx, BioSante, Dendreon

@Delta4_98: "What would be your target price for $CHTP on a CRL?"

Chelsea Therapeutics' (CHTP) stock price will fall if FDA rejects Northera on March 28; how much depends on what demands the agency places on the company in order to resubmit the drug for approval again.

Best case: If Chelsea only needs to negotiate final labeling for Northera and/or make minor fixes to manufacturing, the stock shouldn't drop too much. I hate making guesses on stock prices but let's say a 20% drop. [This assumes a relatively fast resubmission and a three-month response from FDA.]

Worst case: FDA asks for additional clinical data on Northera, Chelsea shares are more likely to fall 50% or more. Chelsea's market value may not fall as much if the company can use Study 306b results expected in third quarter. If an entirely new clinical trial of Northera is needed, the sell off will be more severe.

@BlacknGoldFool: "Can you please remind everyone your take on $KERX? Just want to make sure you get your last bit of hate mail in!"

I'm no fan of Keryx Pharmaceuticals (KERX - Get Report), mainly because I see failure ahead for the phase III study of perifosone in advanced colon cancer.

On Monday, Keryx said that the 360th patient death needed to start the final analysis of the perifosine trial is likely to occur in March. If we assume Keryx is using electronic data capture in the trial, top-line results should be available in April, or May at the latest.

I won't rehash here the myriad reasons for why I predict perifosine won't work, but please revisit my previous columns on how Keryx runs afoul of the so-called Feuerstein-Ratain Rule governing cancer drug development.

@matthewherper, my friend and Forbes drug scribe, asks, "How does Max smell?"

To which, @kevinccc interjected, "With his nose. How do you do it?"

These days, Max (badly in need of a trip to the groomer) smells a lot like those wet towels you left crumpled in the corner of your room for a few days. That and a lingering essence of skunk, the result of an unfortunate encounter a few weeks ago. He's still the best dog in the world.

@HemPaddy: "2012 PDUFA or Adcomm event you strongly believe will be +ve or -ve, that most of the street disagrees with? (not VVUS, CHTP)"

I'm having trouble coming up with a contrarian opinion on an FDA drug approval. I was surprised that nearly all of my picks in TheStreet's FDA Drug Approval Contest line up with the consensus view.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BPAX $55.05 -1.24%
CHTP $0.00 0.00%
DNDN $0.06 -6.02%
GILD $85.60 0.00%
KERX $5.21 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs